# Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Source: https://onco.cc/trials/nct06712316/  
OnCo record `nct06712316` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of PM8002, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by BioNTech SE, now recruiting.

## Summary

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer is a phase 2/3 interventional study registered as NCT06712316 by BioNTech SE, with 1580 participants planned, started 2025-01-07 and due to reach its primary completion in 2029-01. Interventions recorded: Pumitamig, Pembrolizumab, Carboplatin, Pemetrexed, Paclitaxel. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06712316
- Phase: 2/3
- Setting: A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer
- Sponsor: BioNTech SE
- Enrolled: 1580

## Sources

- ClinicalTrials.gov NCT06712316: https://clinicaltrials.gov/study/NCT06712316

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct06712316.json